Dan Rothman

Chief Information Officer, Sumitovant

Dan Rothman serves as Chief Information Officer of Sumitovant and joined Roivant Sciences as Chief Information Officer in 2017. From 2008 to 2017 he was a Managing Director at Goldman Sachs serving as Head of Digital Structuring and Head of the Americas Client Strategy Group, among others. In those positions, he was responsible for the development of internal and external technology platforms, leveraging analytics and data mining tools to optimize various corporate services. He received his B.S. in Electrical Engineering and his M.S. in Electrical Engineering and Computer Science from MIT.

Dan, what would you say are the key opportunities with our two feature platforms, DrugOME and Digital Innovation?

I believe that by making DrugOME and Digital Innovation a fundamental part of our operations, we can greatly accelerate bringing new medicines to patients. Our business ultimately strives to identify the right compound at the right dose in the right patient population and deliver that compound safely but rapidly. We do this not just by employing skilled clinical researchers, but also by leveraging data to accelerate and de-risk every aspect of the drug development process, from bench to bedside. These platforms allow us to remove the traditional divide between IT and the rest of our business, which unlocks tremendous value both for our business and the patients we serve.

What is DrugOME and what makes it different from everything else that is out there?

DrugOME is a unique computational ecosystem that gives fast, high-quality and customized answers to critical pharma questions. Like the human genome, which comprises all the data related to a person’s gene structure and expression, Sumitovant’s DrugOME comprises all data related to drug development, from deal announcements to recently published clinical results. DrugOME is our genome for drug development.

Can you explain the company’s Digital Innovation approach? What is unique about it?

Digital Innovationis an embedded technology capability. Individual technologists and data scientists are embedded directly into our business teams. This enables the development of innovative and bespoke apps, models, and dashboards that visualize critical datasets and support rapid and effective decision making in every part of Sumitovant. In removing the traditional divide between “tech” and the rest of our business, we’re able to integrate custom analytics or process automation into key areas whether in a lab or a board meeting. This approach gives our technologists insight into the most valuable questions that need to be answered, and empowers them to write custom code to interrogate a broader set of inputs than most people may think of using. Sumitovant’s Digital Innovation approach removes unnecessary silos and enables seamless integration, which lets us drive innovation where it matters most.

How do you see these two key features of Sumitovant’s business model – DrugOME and Digital Innovation – evolving over the next few years?

We envision a bright future for both platforms, and we’re only beginning to see the tip of the iceberg. We always ask ourselves, Why guess when we can know? The truth is, many critical questions in drug development have already been asked and answered, and there is a greater richness of data today than ever before to answer new ones. The answers to many of our partners’ questions, for example, are already out there if you know how and where to find them. Sumitovant’s technology platforms allow us to quickly process and understand all this information, and rapidly develop approaches to investigate new problems. This way, our scientists and engineers can apply their creativity and intelligence to solving the truly novel problems that can be most transformative for patients’ lives. 

Back to Voices